[Evolution of patients with rheumatoid arthritis treated with immunosuppressive agents between 1965 and 1973]. 1978

J C Renier, and C Bregeon, and C Bonnette, and M Boasson, and M Bernat, and M Basle, and J Besson, and C Wellinger, and B Bourgeois, and N Teisseire

The authors report the results of a study of 139 of their patients with severe rheumatoid arthritis, treated with chlorambucil of cyclophosphamide between 1965 and December 1973, with an observation period of 4 to 12 years. 8 patients were lost to follow-up, 38 died and 93 were reexamined. In this series 7 deaths were attributed to hemolymphoreticulopathy of various cytological types; 6 deaths were due to visceral cancer and 2 others to cancer of the tonsils. They confirm that such treatments increase the risk of hemopathy but apparently not the risk of visceral cancer. The risk was not a function of the total dose of the drug administered since no neoplasia was observed in the 25 subjects who received the highest doses. The addition of chlorambucil to cyclophosphamide seems to increase the risk of hemopathy. It was noticed that the 7 cases of hemolymphoreticulopathy occured after 60 years.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002699 Chlorambucil A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed) 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid,Amboclorin,CB-1348,Chloraminophene,Chlorbutin,Leukeran,Lympholysin,N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid,NSC-3088,CB 1348,CB1348,NSC 3088,NSC3088
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006402 Hematologic Diseases Disorders of the blood and blood forming tissues. Blood Diseases,Hematological Diseases,Blood Disease,Disease, Blood,Disease, Hematologic,Disease, Hematological,Diseases, Blood,Diseases, Hematologic,Diseases, Hematological,Hematologic Disease,Hematological Disease

Related Publications

J C Renier, and C Bregeon, and C Bonnette, and M Boasson, and M Bernat, and M Basle, and J Besson, and C Wellinger, and B Bourgeois, and N Teisseire
August 1973, Minerva medica,
J C Renier, and C Bregeon, and C Bonnette, and M Boasson, and M Bernat, and M Basle, and J Besson, and C Wellinger, and B Bourgeois, and N Teisseire
January 1972, Reumatologia,
J C Renier, and C Bregeon, and C Bonnette, and M Boasson, and M Bernat, and M Basle, and J Besson, and C Wellinger, and B Bourgeois, and N Teisseire
January 1970, Reumatismo,
J C Renier, and C Bregeon, and C Bonnette, and M Boasson, and M Bernat, and M Basle, and J Besson, and C Wellinger, and B Bourgeois, and N Teisseire
January 1995, Materia medica Polona. Polish journal of medicine and pharmacy,
J C Renier, and C Bregeon, and C Bonnette, and M Boasson, and M Bernat, and M Basle, and J Besson, and C Wellinger, and B Bourgeois, and N Teisseire
November 2005, Arthritis and rheumatism,
J C Renier, and C Bregeon, and C Bonnette, and M Boasson, and M Bernat, and M Basle, and J Besson, and C Wellinger, and B Bourgeois, and N Teisseire
September 1971, The Journal of the Medical Society of New Jersey,
J C Renier, and C Bregeon, and C Bonnette, and M Boasson, and M Bernat, and M Basle, and J Besson, and C Wellinger, and B Bourgeois, and N Teisseire
November 2002, Annals of the rheumatic diseases,
J C Renier, and C Bregeon, and C Bonnette, and M Boasson, and M Bernat, and M Basle, and J Besson, and C Wellinger, and B Bourgeois, and N Teisseire
February 1987, The Journal of rheumatology,
J C Renier, and C Bregeon, and C Bonnette, and M Boasson, and M Bernat, and M Basle, and J Besson, and C Wellinger, and B Bourgeois, and N Teisseire
January 2016, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi,
J C Renier, and C Bregeon, and C Bonnette, and M Boasson, and M Bernat, and M Basle, and J Besson, and C Wellinger, and B Bourgeois, and N Teisseire
December 1981, Recenti progressi in medicina,
Copied contents to your clipboard!